North America held the maximum revenue share in 2018 and it is expected to lead in the forecast period, growing at a CAGR of 3.9% during 2019–2026 -GMI Research

global Anti-Epileptic Drugs market

The Global Anti-Epileptic Drugs Market was valued at USD 3,323.0 million in 2018, and is expected to reach USD 4,458.0 million by 2026, growing at a CAGR of 3.8% during 2019–2026. The major driving factors of the anti-epileptic drugs market is the rising awareness about epilepsy and new drug approvals over the past few years. Advancements in Drug structure of Anti-Epileptic Drugs and increasing social awareness about the evolved drug type are likely to drive the growth of global Anti-Epileptic Drugs market in near future.

Furthermore, advancements in medication management and improvement in healthcare services coupled with increasing number of drug approvals across the globe have led to burgeoning market growth of Anti-Epileptic Drugs market.

Valporic Acid drug segment is expected to dominate global Anti-Epileptic Drugs market during the forecast period. In 2018, Almost half of the market share was held by Valporic Acid drug in the component segment. However, the highest growth rate is expected to be witnessed by the Lacosamide component segment during the forecast period owing to increase in usage in in the treatment of partial-onset seizures.

Major Players are focussing on implementation of healthcare services and also making the drug structure more homogenous to keep leadership in the competitive Anti-Epileptic Drugs market. For example, On January 2017, Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC.”—GMI Research

Based on geography, North America held the largest share in the market in 2018 because of rising awareness about the disease and treatment available, increase in number of rehabs and surgical centers in the region and exponential increase in the population regarding anti-epileptic drugs. In addition, there has been a rise in the number of approved anti- epileptic drugs. Asia – Pacific region is expected to have the highest growth rate in the forecast years due to high incidence rate of epilepsy diseases.

Key Market Developments:

  • In 2018, the Valporic Acid drug type held more than half of the market share.
  • Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Valeant Pharmaceuticals are the leading players holding around one third of the market share.
  • Lacosamide drug type is anticipated to grow at the highest rate during the forecast period from 2019 to 2026.
  • Broad Spectrum is the emerging spectrum segment in the Anti-Epileptic Drugs field, which is intended to cater to the unmet needs of the Anti-Epileptic Drugs market.
  • North America region occupied maximum revenue share in global Anti-Epileptic Drugs market in 2018.

Some of the key players operating in global Anti-Epileptic Drugs market include Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Valeant Pharmaceuticals International, Sanofi S.A, UCB Pharma Ltd, GlaxoSmithKline plc, Johnson & Johnson, Novartis, AG, Pfizer Inc among others.

The Global Anti-Epileptic Drugs Market has been segmented on the basis of spectrum type, the market comprises of Narrow and Broad Spectrum. The drug type includes Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide.

For more details, browse the Table of Contents: https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-by-spectrum-type/
Early buyers will get customization upto 25% on report

Contact Sarah Nash
Tel: +353 1 536 3035
U.S Office +1 860 881 2270
Europe Office +353 1 442 8820
Email: enquiry@gmiresearch.com